Fosun Pharma (02196) released an announcement that on March 31, 2025, the company re -purchased a total of 1,613,300 a shares (accounting for approximately 0.0604% of the total capital of sharing Japanese companies until March 31, 2025), and the combined amount of repayment costs approximately RMB 39.99441 million (which does not exclude transaction fees). 基于认识到其对可持续发展的信心和价值，该公司将加速在重新购买期间的A股共享的实施，以增强投资者的信心并保护投资者的利益。 金融的官方帐户 24小时广播滚动滚动最新的财务和视频信息，并扫描QR码，以获取更多粉丝效仿的好处（Sinafinance）